Oral erythromycin for treatment of gastrointestinal dysmotility in premature infants
Keywords:
erythromycin, gastrointestinal dysmotility, preterm infants
Abstract
Background Functional immaturity of gastrointestinal (GI)motility predisposes preterm infants to feeding intolerance.
Erythromycin as a prokinetic agent has been given to preterm
infants for the management of non-obstructive GI dysmotility.
Objective To evaluate the efficacy of oral erythromycin for the
treatment of GI dysmotility in preterm infants.
Methods A randomized controlled clinical trial was done at Adam
Malik Hospital and Pirngadi Hospital, Medan, between October
2004 – March 2005. Fifty preterm infants with feeding intolerance
were randomly assigned to either receive oral erythromycin (12.5
mg/kg, every 6 hours) or placebo for 7 days. Improved tolerance
for enteral feedings was evaluated by the amount of gastric residue
before feeding.
Results On the sixth day, there was a significant difference in the
amount of residue from gastric residue between the oral
erythromycin group and placebo group (mean 21.7 and 29.4;
P<0.05) and so were results on the seventh day (mean 14.1 and
26.9; P<0.05).
Conclusion Oral erythromycin reduces the amount of gastric
residue before feed in premature infants.
References
1. Milla PJ. Intestinal motility and its disorders in childhood.
In: Lebenthal E, editor. Textbook of gastroenterology and
nutrition in infancy. 2 th ed. New York: Raven Press; 1989. p.
1293-1309.
2. Kliegman RM. Studies of feeding intolerance in very low birth
weight infants: Definition and significance. Pediatrics 2002;
109:516-7.
3. Stenson BJ, Middlemist L, Lyon AJ. Influence of erythromycin
on establishment of feeding in preterm infants: observations
from a randomised controlled trial. Arch Dis Child Fetal
Neonatal 1998;79:F212-4.
4. Madani A, Pishva N, Pourarian SH, Zarkesh M. The efficacy
of oral erythromycin in enhancement of milk tolerance in
premature infants: a randomised clinical trial. IJMS 2004;
29:1-4.
5. Massachusets Poison Control System. Erythromycin. Clinical
toxicology review 1995. Available from URL: http://
www.maripoisoncenter.com/ctr/9560erythromycin.html.
6. Poets CF. Gastroesophageal reflux: A critical review of its
role in preterm infants. Pediatrics 2004;113:e128-32.
7. Ng PC, So KW, Fung KSC, Lee CH, Fok TH, Wong E et al.
Randomised controlled study of oral erythromycin for
treatment of gastrointestinal dysmotility in preterm infants.
Arch Dis Child Fetal Neonatal 2001;84:F177-82.
8. Zatman TF, Hall JE, Harmer M. Gastric residual volume in
children: a study comparing efficiency of erythromycin and
metoclopramide as prokinetic agents. British Journal of
Anasthesia 2001;86:869-71.
9. Wyllie. Motility disorders and hirschsprung disease. In:
Behrman RE, Kliegman RM, Jenson HB, editors. Nelson
textbook of pediatrics. 16 th ed. Philadelphia: Saunders, 2000;
p. 1138-9.
10. Coulie B, Tack J, Peeters T, Janssens J. Involvement of two
different pathways in the motor effects of erythromycin on
the gastric antrum in humans. Gut 1998;43:395-400.
11. Jadcheria SR, Berseth CL. Effect of erythromycin on
gastroduodenal contractile activity in developing neonates.
J Pediatr Gastrol Nutr 2002;34:16-22.
12. Miller P, Roy A, St-Pierre S, Dagenals M, Lapointe R, Poitras
P. Motilin receptors in the human antrum. Am J Physol 2000;
278:618-23.
13. Peeters T, Matthijs G, Depoortene I, Cachet T, Hoogmartens
J, Vantrappen G. Erythromycin is a motilin receptor agonist.
Am J Physiol 1989;257:G470-4.
14. Amir I, Rohsiswatmo R, Kaban RK. Penatalaksanaan bayi berat
badan lahir rendah. In: Rusdidjas, Dasa Tjipta G, editors.
Makalah lengkap kongres nasional VIII perinasia & simposium
internasional. Medan: BIKA FK USU; 2003. p. 500-16.
15. Patole SK, Rao S, Doherty D. Erythromycin as a prokinetic
agent in preterm neonates-a systematic review. Arch Dis
Child Fetal Neonatal 2005;90:F301-6.
16. Slater-Myer LP, Saslow JG, Stahl GE. Development of the
gastrointestinal tract. In: Spitzer AR, editor. Intensive care
of the fetus and neonate. St Louis: Mosby; 1996. p. 843-56.
In: Lebenthal E, editor. Textbook of gastroenterology and
nutrition in infancy. 2 th ed. New York: Raven Press; 1989. p.
1293-1309.
2. Kliegman RM. Studies of feeding intolerance in very low birth
weight infants: Definition and significance. Pediatrics 2002;
109:516-7.
3. Stenson BJ, Middlemist L, Lyon AJ. Influence of erythromycin
on establishment of feeding in preterm infants: observations
from a randomised controlled trial. Arch Dis Child Fetal
Neonatal 1998;79:F212-4.
4. Madani A, Pishva N, Pourarian SH, Zarkesh M. The efficacy
of oral erythromycin in enhancement of milk tolerance in
premature infants: a randomised clinical trial. IJMS 2004;
29:1-4.
5. Massachusets Poison Control System. Erythromycin. Clinical
toxicology review 1995. Available from URL: http://
www.maripoisoncenter.com/ctr/9560erythromycin.html.
6. Poets CF. Gastroesophageal reflux: A critical review of its
role in preterm infants. Pediatrics 2004;113:e128-32.
7. Ng PC, So KW, Fung KSC, Lee CH, Fok TH, Wong E et al.
Randomised controlled study of oral erythromycin for
treatment of gastrointestinal dysmotility in preterm infants.
Arch Dis Child Fetal Neonatal 2001;84:F177-82.
8. Zatman TF, Hall JE, Harmer M. Gastric residual volume in
children: a study comparing efficiency of erythromycin and
metoclopramide as prokinetic agents. British Journal of
Anasthesia 2001;86:869-71.
9. Wyllie. Motility disorders and hirschsprung disease. In:
Behrman RE, Kliegman RM, Jenson HB, editors. Nelson
textbook of pediatrics. 16 th ed. Philadelphia: Saunders, 2000;
p. 1138-9.
10. Coulie B, Tack J, Peeters T, Janssens J. Involvement of two
different pathways in the motor effects of erythromycin on
the gastric antrum in humans. Gut 1998;43:395-400.
11. Jadcheria SR, Berseth CL. Effect of erythromycin on
gastroduodenal contractile activity in developing neonates.
J Pediatr Gastrol Nutr 2002;34:16-22.
12. Miller P, Roy A, St-Pierre S, Dagenals M, Lapointe R, Poitras
P. Motilin receptors in the human antrum. Am J Physol 2000;
278:618-23.
13. Peeters T, Matthijs G, Depoortene I, Cachet T, Hoogmartens
J, Vantrappen G. Erythromycin is a motilin receptor agonist.
Am J Physiol 1989;257:G470-4.
14. Amir I, Rohsiswatmo R, Kaban RK. Penatalaksanaan bayi berat
badan lahir rendah. In: Rusdidjas, Dasa Tjipta G, editors.
Makalah lengkap kongres nasional VIII perinasia & simposium
internasional. Medan: BIKA FK USU; 2003. p. 500-16.
15. Patole SK, Rao S, Doherty D. Erythromycin as a prokinetic
agent in preterm neonates-a systematic review. Arch Dis
Child Fetal Neonatal 2005;90:F301-6.
16. Slater-Myer LP, Saslow JG, Stahl GE. Development of the
gastrointestinal tract. In: Spitzer AR, editor. Intensive care
of the fetus and neonate. St Louis: Mosby; 1996. p. 843-56.
Published
2007-10-31
How to Cite
1.
Moesri A, Lubis B, Asrul A, Sinuhaji A, Tjipta G. Oral erythromycin for treatment of gastrointestinal dysmotility in premature infants. PI [Internet]. 31Oct.2007 [cited 23Dec.2024];47(5):234-. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/421
Section
Articles
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Received 2016-09-01
Accepted 2016-09-01
Published 2007-10-31
Accepted 2016-09-01
Published 2007-10-31
